RecruitingNCT06432894

Performance Evaluation of ANI in Patients Under General Anesthesia With Remimazolam

Performance Evaluation of Analgesia Nociception Index (ANI) in Patients Under General Anaesthesia With Remimazolam: a Prospective Observational Study


Sponsor

Catholic Kwandong University

Enrollment

30 participants

Start Date

Apr 23, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to determine whether Analgesia Nociception Index (ANI) can effectively reduce the dose of opioid in patients who underwent general anesthesia using remimazolam.


Eligibility

Min Age: 20 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Analgesia Nociception Index, remimazolam for people with pain measurement. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years to 79 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTAnalgesia Nociception Index, remimazolam

The purpose of this study is to determine the validity of ANI in patients undergoing surgery with remifentanil and remimazolam. During this study, remimazolam infusion rate is determined by the pharmacopoeia. Remifentanil infusion rate is determined based on the patient's vital signs, systemic status and pain levels. And remifentanil is administrated via targeted infusion control using the Minto model. ANI scores, vital signs, remifentanil infusion rate are collected at predetermined time points according to the protocol from the start to the end of the surgery.


Locations(1)

Catholic-Kwandong University, School of Medicine

Incheon, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06432894


Related Trials